专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明公开

EP1560603A1 VERFAHREN ZUR MESSUNG DES METABOLISMUS DER BAUCHSPEICHELDRÜSE 有权
标题翻译：法测量代谢胰腺癌的
公开(公告)号：EP1560603A1
公开(公告)日：2005-08-10
申请号：EP03776893.4
申请日：2003-11-10
申请人： Infai Institut für Biomedizinische Analytik und NMR-Imaging GMBH
发明人： AYGEN, Sitke,INFAI Inst. für biomed. Analyzik Und
IPC分类号： A61K51/12 , A61K49/00
CPC分类号： A61K51/1206 , A61K49/0004
摘要： Disclosed is a method for measuring pancreatic metabolism, which is characterized by the fact that the increase in 13CO2 in the exhaled breath is determined prior to and following the intravenous application of secretin as well as prior to and following the oral application of a 13C triglyceride.

62. 发明公开

EP1478407A1 USE OF 13C LABELLED SUBSTANCE FOR MEASURING LUNG FUNCTION 审中-公开
标题翻译：作者13C LABELED物质用于测量肺功能使用
公开(公告)号：EP1478407A1
公开(公告)日：2004-11-24
申请号：EP03708936.4
申请日：2003-02-26
申请人： Cambridge Isotope Laboratories, Inc.
发明人： IRIE, Yasuo , MODAK, Anil, S.
IPC分类号： A61K51/04
CPC分类号： A61K51/1206 , A61K49/00 , A61K49/0004
摘要： The present invention relates to an assay for evaluating alveolar exchange of oxygen. A 13C-labeled substrate, such as 13C-sodium bicarbonate is administered to a subject by oral or iv intake, and exhaled 13CO2 is measured. The 13CO2 in expired breath can be collected at various time points following administration of the substrate and measured in Δ per mil with a mass analyzer or photometer, such as an IR spectrometer. This process can be used as a diagnostic test for the indication of, treatment and/or evaluation of the severity of respiratory tract diseases or infections.

63. 发明授权

EP0787017B1 DIAGNOSTIC PREPARATION FOR DETECTION OF HELICOBACTER PYLORI 失效
标题翻译：跟踪幽门螺杆菌的诊断研制
公开(公告)号：EP0787017B1
公开(公告)日：2004-08-11
申请号：EP95936815.0
申请日：1995-10-17
申请人： Orexo AB
发明人： NYSTRÖM, Christer , LUNDQVIST, Thomas , PETTERSSON, Anders
IPC分类号： A61K49/00 , A61K51/00
CPC分类号： A61K51/1206 , A61K51/0406
摘要： The present invention relates to a preparation for administering isotope-labelled urea together with acid in tablet form, in the form of a capsule preparation, or in some other solid form. The preparation dissolves very quickly in the stomach. The preparation is used to show increased urease activity in the stomach in association with an ongoing Helicobacter pylori infection.

64. 发明公开

EP1386934A1 Diagnostic agents for pancreatic exocrine function 有权
标题翻译： Diagnostikfürdie exokrine Funktion derBauchspeicheldrüse
公开(公告)号：EP1386934A1
公开(公告)日：2004-02-04
申请号：EP03077521.7
申请日：1999-09-24
申请人： Tokyo Gas Company Limited
发明人： Kohno, Tadashi , Hosoi, Isaburo , Ohshima, Junko , Shibata, Kunihiko , Ito, Asuka
IPC分类号： C08B30/00 , C08B37/16 , C08B37/00 , A61K51/00 , A61K47/26 , A61K51/12 , A61K49/00
CPC分类号： A61K51/0491 , A61K49/06 , A61K49/1815 , A61K49/189 , A61K51/06 , A61K51/1206 , A61K51/1268 , B82Y5/00 , C08B37/00
摘要： The present invention provides a 13 C-labeled oligosaccharide or polysaccharide or a salt thereof excluding U- 13 C-maltose, 13 C-starch, 1- 13 C-maltotetraose and 1- 13 C-amylose; a derivative of the 13 C-labeled oligosaccharide or polysaccharide or salt thereof; a 13 C-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host molecule; a 13 C- or 14 C-labeled fluorescein ester compound or a salt thereof; and a diagnostic agents for pancreatic exocrine function comprising these compounds 13 C- or 14 C-labeled.
摘要翻译：本发明提供了一种13 C-标记的寡糖或多糖或其盐，不包括U-13 C-麦芽糖，13 C-淀粉，1- 13 C-麦芽四糖和1 -13 C -amylose; 13 C-标记的寡糖或多糖或其盐的衍生物; 包含环糊精或其修饰的衍生物作为宿主分子的13 C-标记的包合物或其盐， 13 C-或14 C-标记的荧光素酯化合物或其盐; 以及包含这些化合物13 C-或14 C-标记的胰外分泌功能的诊断剂。

65. 发明公开

EP1385476A2 METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS 审中-公开
标题翻译： WHY（丝博）诊断和薄细菌过度生长的治疗方法及相关疾病
公开(公告)号：EP1385476A2
公开(公告)日：2004-02-04
申请号：EP02725704.7
申请日：2002-04-16
申请人： CEDARS-SINAI MEDICAL CENTER
发明人： LIN, Henry, C. , PIMENTEL, Mark
IPC分类号： A61K9/00
CPC分类号： A61K38/54 , A23L33/40 , A23V2002/00 , A61B5/0836 , A61B5/412 , A61B5/415 , A61B5/418 , A61K9/0053 , A61K9/0087 , A61K31/135 , A61K31/138 , A61K31/198 , A61K31/201 , A61K31/353 , A61K31/4045 , A61K31/4164 , A61K31/4184 , A61K31/424 , A61K31/43 , A61K31/496 , A61K31/65 , A61K31/7036 , A61K31/7048 , A61K36/534 , A61K38/1796 , A61K38/22 , A61K38/225 , A61K38/2271 , A61K45/06 , A61K49/0004 , A61K51/1206 , G01N33/497 , G01N33/6893 , G01N2033/4977 , G01N2333/70571 , G01N2800/06 , Y10S426/80 , Y10S426/801 , Y10T436/145555 , Y10T436/147777 , Y10T436/18 , Y10T436/214 , Y10T436/22 , A61K2300/00
摘要： Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.
摘要翻译：公开的是在人受试者中检测小肠细菌过度生长（SIBO）的方法。该方法涉及检测甲烷，氢气的相对量，和至少一个在由所述人受试者呼出的气体混合物的气体含硫，之后所述的人类受试者摄食过基板的控制量，所述气体混合物至少部分地通过所述的人类受试者的肠道菌群产生。被检查的检测方法的试剂盒等等游离缺失盘。

66. 发明公开

EP1312381A1 PREPARATIONS FOR MEASRUING GASTRIC pH VALUE AND METHOD OF MEASURING GASTRIC pH VALUE BY USING THE SAME 审中-公开
标题翻译：用于测量胃内pH值的筹备和测量胃液pH使用它的方法
公开(公告)号：EP1312381A1
公开(公告)日：2003-05-21
申请号：EP01941167.7
申请日：2001-06-21
申请人： OTSUKA PHARMACEUTICAL CO., LTD.
发明人： INADA, Makoto , NODA, Atsunari , IKEI, Nobuhiro
IPC分类号： A61K51/12 , A61K33/10 , A61K9/00 , A61K47/32 , A61K47/38
CPC分类号： A61K51/1206 , A61K51/02
摘要： The present invention provides a preparation for easily and non-invasively measuring gastric pH, for example, a preparation for measuring gastric pH using the expired air, and a method for measuring gastric pH using the preparation. The preparation of the present invention can be produced by covering a composition containing a compound labeled with an isotope ( 13 C, 14 C, 15 N, or 18 O), with a pH-dependent soluble base.
摘要翻译：本发明提供一种用于非侵入性地测量和轻松胃pH，对于实施例的制剂，用于使用所述呼出气体测定胃pH的制剂，以及使用该制剂测量胃内pH的方法。本发明的制剂可以通过覆盖包含被同位素标记的化合物的组合物（<13> C，<14> C，<15> N，或<18> O），具有pH依赖性可溶性基来制备，

67. 发明公开

EP1304124A1 Diagnostic agent for diabetes comprising 13C labelled compound 有权
标题翻译：诊断糖尿病，13C-markierte Zusammensetzungenthält
公开(公告)号：EP1304124A1
公开(公告)日：2003-04-23
申请号：EP03000243.0
申请日：1998-10-19
申请人： Tokyo Gas Co., Ltd.
发明人： Kohno, Tadashi , Hosoi, Isaburo , Oshima, Junko , Ito, Asuka , Shibata, Kunihiko
IPC分类号： A61K51/04 , A61P3/00
CPC分类号： A61K51/1206 , A61K49/1815
摘要： The present invention relates to a diagnostic agent for diabetes, comprising a compound labelled with 13 C at least at one specific position selected from the group consisting of the following (a) to (g):

(a) galactose, fructose or xylose labelled with 13 C at least at one specific position, or a starch composed of glucose units labelled with 13 C at least at one specific position;
(b) an amino acid labelled with ''C at least at one specific position;
(c) lactic acid or citric acid labelled with 13 C at least at one specific position;
(d) a fatty acid labelled with 13 C at least at one specific position;
(e) a glyceride labelled with 13 C at least at one specific position;
(f) glycerol labelled with 13 C at least at one specific position; and
(g) aminopyrin of which the dimethylamino group at position 4 is labelled with 13 C, phenacetin of which the ethoxy group is labelled with 13 C at position 1, or methacetin of which the methoxy group is labelled with 13 C.
摘要翻译：本发明涉及一种用于糖尿病的诊断剂，其包含至少在选自以下（a）至（g）中的至少一个特定位置上标记的化合物：（a）半乳糖，果糖或木糖至少在一个特定位置标记为13 C，或由至少在一个特定位置由13 C标记的葡萄糖单元组成的淀粉; （b）至少在一个特定位置用“C”标记的氨基酸; （c）至少在一个特定位置用13 C标记的乳酸或柠檬酸; （d）至少在一个特定位置用13 C标记的脂肪酸; （e）至少在一个特定位置用13 C标记的甘油酯; （f）至少在一个特定位置用13 C标记的甘油; 和（g）其中位置4的二甲基氨基被标记为13 C的氨基吡啶，其中乙氧基在13位被标记为13 C的美沙西丁，其中甲氧基被标记为<13 >℃。

68. 发明授权

EP0913161B1 Use of a 13C-labelled amino acid as a diagnostic agent for diabetes 有权
标题翻译：对于糖尿病的诊断中使用13C标记的氨基酸的
公开(公告)号：EP0913161B1
公开(公告)日：2003-03-26
申请号：EP98308523.4
申请日：1998-10-19
申请人： Tokyo Gas Co., Ltd.
发明人： Kohno, Tadashi , Hosoi, Isaburo , Ohshima, Junko , Ito, Asuka , Shibata, Kunihiko
IPC分类号： A61K51/04 , A61P43/00
CPC分类号： A61K51/1206 , A61K49/1815

69. 发明授权

EP1044692B1 Verfahren und Vorrichtung zum trockenen Anbringen von Substanzen an inhalierbare pulverförmige Trägerstoffe 有权
标题翻译：用于施加干物质的可吸入粉末的载体物质的方法和装置
公开(公告)号：EP1044692B1
公开(公告)日：2003-02-19
申请号：EP00107004.4
申请日：2000-03-30
申请人： GSF-Forschungszentrum für Umwelt und Gesundheit GmbH
发明人： Scheuch, Gerhard , Sommerer, Knut
IPC分类号： A61K51/12
CPC分类号： A61K51/1206

70. 发明公开

EP1089765A2 $i(IN VIVO) DETERMINATION OF METABOLIC FUNCTION FOR USE IN THERAPY MANAGEMENT 审中-公开
标题翻译：在代谢功能在治疗中的管理体测定
公开(公告)号：EP1089765A2
公开(公告)日：2001-04-11
申请号：EP99937189.1
申请日：1999-06-29
申请人： Phenome Sciences Inc.
发明人： AJAMI, Alfred, M.
IPC分类号： A61K49/00 , A61K51/04 , A61K51/12 , C12Q1/34 , C12Q1/37 , C12Q1/527 , C12Q1/48 , C12Q1/44 , C12Q1/52 , C12Q1/26 , C12Q1/28
CPC分类号： A61K51/1206
摘要： It is an object of the present invention to provide in vivo analytical methods that allow for diagnosis and management of therapy for diseases involving discrete biochemical pathways. In the method of the invention, a labelled tracer probe, a specifically designed substrate of a 'gateway' enzyme, an enzyme marking a regulatory point in a discrete biochemical pathway, is administered to a subject; a labelled product of the action of the enzyme is measured; and the appearance and concentration of the product are related to the disease condition of interest. Determination of the rate of substrate-product conversion of the gateway enzyme allows for the analysis to be made. The method involves administering a defined amount of a labelled 'metaprobe' substrate of the gateway enzyme to a subject, at a site that provides access to a desired pool of the gateway enzyme in the subject, and measuring the amount of the chosen labelled product. The presence and amount of the chosen labelled product in, e.g., the breath, definitely indicates that the labelled metaprobe has been metabolized by the specific enzyme in the specific biochemical pathway under consideration, and from the calculated rate of substrate-product conversion by the gateway enzyme, the desired diagnostic determination may be made. Likewise, if a specific therapeutic treatment for a disease is underway with a patient, this method allows for a minimally invasive assessment of the effectiveness of the treatment, with minimal discomfort to the patient.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式